Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegen...
Alumis Inc. (ALMS)
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis” or the “Company”), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced the Company will give two data presentations on A-005, a potent, selective, central nervous system (CNS) penetrant tyrosine kinase 2 (TYK2) inhibitor, on Friday, February 28, 2025, at the 10th Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025. “These data demonstrate that A-005 potently inhibits TYK2-specific signaling in immune cells and CNS r
Read more
Impact Snapshot
Event Time:
ALMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALMS alerts
High impacting Alumis Inc. news events
Weekly update
A roundup of the hottest topics
ALMS
News
- Alumis Inc. (NASDAQ: ALMS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.MarketBeat
- Alumis to Present at Leerink's 2025 Global Healthcare ConferenceGlobeNewswire
- Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in PsoriasisGlobeNewswire
- Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger [Yahoo! Finance]Yahoo! Finance
- Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed MergerGlobeNewswire
ALMS
Sec Filings
- 3/10/25 - Form 8-K
- 3/4/25 - Form 8-K
- 2/21/25 - Form 8-K
- ALMS's page on the SEC website